Research Analysts’ Weekly Ratings Updates for Sensei Biotherapeutics (FTH)

Sensei Biotherapeutics (NASDAQ: FTH) has recently received a number of price target changes and ratings updates:

• 11/4/2026 – Sensei Biotherapeutics had its price target lowered by Guggenheim from $70.00 to $69.00. They now have a “buy” rating on the stock.
• 10/27/2026 – Sensei Biotherapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $55.00 price target on the stock.
• 10/16/2026 – Sensei Biotherapeutics is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – Sensei Biotherapeutics was upgraded by Lifesci Capital to “strong-buy”.
• 9/26/2026 – Sensei Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/16/2026 – Sensei Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $70.00 price target on the stock.
• 9/15/2026 – Sensei Biotherapeutics was upgraded by Guggenheim to “strong-buy”.
• 9/14/2026 – Sensei Biotherapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/9/2026 – Sensei Biotherapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.

Sensei Biotherapeutics Price Performance

FTH stock traded down $0.16 during trading on Thursday, hitting $19.83. The stock had a trading volume of 270,491 shares, compared to its average volume of 252,636. Sensei Biotherapeutics, Inc. has a twelve month low of $7.45 and a twelve month high of $42.14. The business’s 50-day moving average price is $27.95. The stock has a market cap of $512.41 million, a PE ratio of -0.14 and a beta of -0.15.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.13). As a group, equities analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current fiscal year.

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.